Compare Lupin Ltd with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs UNICHEM LAB - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN UNICHEM LAB LUPIN/
UNICHEM LAB
 
P/E (TTM) x 48.4 62.8 77.1% View Chart
P/BV x 2.5 0.7 367.9% View Chart
Dividend Yield % 0.0 2.1 -  

Financials

 LUPIN   UNICHEM LAB
EQUITY SHARE DATA
    LUPIN
Mar-19
UNICHEM LAB
Mar-19
LUPIN/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs986292 337.7%   
Low Rs720182 395.8%   
Sales per share (Unadj.) Rs369.5167.7 220.4%  
Earnings per share (Unadj.) Rs13.4-3.6 -369.2%  
Cash flow per share (Unadj.) Rs37.45.9 629.2%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs303.7372.3 81.6%  
Shares outstanding (eoy) m452.4970.38 642.9%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.31.4 163.4%   
Avg P/E ratio x63.6-65.3 -97.5%  
P/CF ratio (eoy) x22.839.9 57.2%  
Price / Book Value ratio x2.80.6 441.3%  
Dividend payout %0-110.2 0.0%   
Avg Mkt Cap Rs m386,06416,680 2,314.5%   
No. of employees `00017.72.6 679.6%   
Total wages/salary Rs m31,5132,393 1,316.8%   
Avg. sales/employee Rs Th9,453.84,535.2 208.5%   
Avg. wages/employee Rs Th1,782.0919.8 193.7%   
Avg. net profit/employee Rs Th343.0-98.2 -349.3%   
INCOME DATA
Net Sales Rs m167,18211,801 1,416.7%  
Other income Rs m3,640984 369.9%   
Total revenues Rs m170,82212,785 1,336.2%   
Gross profit Rs m28,822-835 -3,452.2%  
Depreciation Rs m10,850674 1,610.5%   
Interest Rs m3,07875 4,093.5%   
Profit before tax Rs m18,534-600 -3,090.5%   
Minority Interest Rs m-890-   
Prior Period Items Rs m381 5,357.1%   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,017-343 -2,625.2%   
Profit after tax Rs m6,066-256 -2,373.7%  
Gross profit margin %17.2-7.1 -243.7%  
Effective tax rate %48.757.3 84.9%   
Net profit margin %3.6-2.2 -167.5%  
BALANCE SHEET DATA
Current assets Rs m138,53620,384 679.6%   
Current liabilities Rs m61,2995,029 1,218.9%   
Net working cap to sales %46.2130.1 35.5%  
Current ratio x2.34.1 55.8%  
Inventory Days Days84105 80.0%  
Debtors Days Days112135 83.4%  
Net fixed assets Rs m127,5169,023 1,413.2%   
Share capital Rs m905141 642.8%   
"Free" reserves Rs m136,51726,058 523.9%   
Net worth Rs m137,42226,199 524.5%   
Long term debt Rs m66,4170-   
Total assets Rs m279,49431,496 887.4%  
Interest coverage x7.0-7.0 -100.7%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.4 159.7%   
Return on assets %3.3-0.6 -571.4%  
Return on equity %4.4-1.0 -452.5%  
Return on capital %8.9-2.0 -445.6%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,4148,188 725.6%   
Fx outflow Rs m22,282596 3,738.6%   
Net fx Rs m37,1327,592 489.1%   
CASH FLOW
From Operations Rs m16,660-3,278 -508.3%  
From Investments Rs m-32,825-2,860 1,147.7%  
From Financial Activity Rs m7,441-24 -30,749.2%  
Net Cashflow Rs m-8,724-4,690 186.0%  

Share Holding

Indian Promoters % 46.6 50.1 93.0%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 15.1 74.8%  
FIIs % 31.9 3.0 1,063.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 31.7 31.9%  
Shareholders   98,259 20,176 487.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 20, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS